Entero Therapeutics Faces Delisting Concerns

TL;DR

Entero Therapeutics might get delisted, filing an 8-K on Jan 7th.

AI Summary

Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) filed an 8-K on January 13, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was January 7, 2025. The company is incorporated in Delaware and its principal business address is in Boca Raton, Florida.

Why It Matters

This filing indicates potential issues with Entero Therapeutics' continued listing on an exchange, which could significantly impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued operation as a publicly traded entity.

Key Players & Entities

• Entero Therapeutics, Inc. (company) — Registrant
• First Wave BioPharma, Inc. (company) — Former company name
• AzurRx BioPharma, Inc. (company) — Former company name
• BioPharma d'Azur, Inc. (company) — Former company name
• January 7, 2025 (date) — Earliest event reported
• January 13, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• Boca Raton, Florida (location) — Business address

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO Nasdaq Capital Marke

Filing Documents

• tm252903d1_8k.htm (8-K) — 26KB
• 0001104659-25-003048.txt ( ) — 196KB
• fwbi-20250107.xsd (EX-101.SCH) — 3KB
• fwbi-20250107_lab.xml (EX-101.LAB) — 33KB
• fwbi-20250107_pre.xml (EX-101.PRE) — 22KB
• tm252903d1_8k_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 7, 2025, Entero Therapeutics, Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5620(a), due to the Company not holding an annual meeting of stockholders in 2024 within one year of the Company's 2023 fiscal year end. The Company has until February 21, 2025, which is 45 days from the date of the Notice, to submit a plan to regain compliance and, if Nasdaq accepts the plan, it may grant up to 180 calendar days from the fiscal year end, or until June 30, 2025, for the Company to regain compliance for continued listing. The Company intends to hold an annual meeting of shareholders as soon as practicable in order to regain compliance with Nasdaq Listing Rule 5620(a). The Company is working towards scheduling such meeting and the meeting's date will be provided on further notice. The Company will also be filing a proxy statement for such meeting with the Securities and Exchange Commission. The notice has no immediate effect on the listing or trading of the Company's common stock. The Company will seek to regain compliance with all applicable Nasdaq requirements within the allotted compliance periods. If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5620(a) or will otherwise be able to maintain compliance with other Nasdaq listing criteria.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. January 13, 2025 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR